Similar articles

Abstract: hepatocellular carcinoma (HCC) is one of the most prevalent malignant tumors worldwide. liver transplantation (LT) is known as a curative and therapeutic modality. However, the survival rates of recipients after LT are still not good enough because of tumor recurrence. To improve the survival rates of recipients after LT, identifying predictive factors for prognosis after LT and establishing a model assessing prognosis are very important to HCC patients. There has recently been a lot of clinical and basic research on recurrence and prognosis after LT. Progress has been made, especially in selection criteria for LT recipients and risk factors for predicting prognosis after LT. Hangzhou criteria, in line with China’s high current incidence rate of primary liver, are first proposed by Chinese scholars of LT, and are accepted world-wide, and make an important contribution to the development of LT.

肝癌肝移植术后受体预后相关因素的研究进展

[1]Agopian VG, Harlander-Locke M, Zarrinpar A, et al., 2015. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients. J Am Coll Surg, 220(4):416-427.

[2]Ahn CS, Moon DB, Lee SG, et al., 2014. Survival differences between Milan criteria after down-staging and De novo Milan in living donor liver transplantation for hepatocellular carcinoma. Hepatogastroenterology, 61(129):187-191.

[3]Akoad ME, Pomfret EA, 2015. Surgical resection and liver transplantation for hepatocellular carcinoma. Clin Liver Dis, 19(2):381-399.

[4]Audet M, Panaro F, Piardi T, et al., 2009. Are the Hangzhou criteria adaptable to hepatocellular carcinoma patients for liver transplantation in Western countries? Liver Transpl, 15(7):822-823.

[5]Balogh J, Victor D 3rd, Asham EH, et al., 2016. Hepatocellular carcinoma: a review. J. Hepatocell Carcinoma, 3:41-53.

[6]Chan SC, 2013. Liver transplantation for hepatocellular carcinoma. Liver Cancer, 2(3-4):338-344.

[7]Ciccarelli O, Lai Q, Goffette P, et al., 2012. Liver transplantation for hepatocellular cancer: UCL experience in 137 adult cirrhotic recipients. Alpha-foetoprotein level and locoregional treatment as refined selection criteria. Transpl Int, 25(8):867-875.

[8]Duvoux C, Roudot-Thoraval F, Decaens T, et al., 2012. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology, 143(4):986-994.e3.

[9]Fan ST, 2008. Selection of HCC patients for liver transplantation: the Milan criteria, Hangzhou criteria and beyond. Hepatobiliary Pancreat Dis Int, 7(3):233-234.

[10]Ferreira MV, Chaib E, Nascimento MU, et al., 2012. Liver transplantation and expanded Milan criteria: does it really work? Arq Gastroentero, 49(3):189-194.

[11]Grąt M, Kornasiewicz O, Lewandowski Z, et al., 2014. Combination of morphologic criteria and α-fetoprotein in selection of patients with hepatocellular carcinoma for liver transplantation minimizes the problem of posttransplant tumor recurrence. World J Surg, 38(10):2698-2707.

[12]Guerrini GP, Pinelli D, di Benedetto F, et al., 2015. Predictive value of nodule size and differentiation in HCC recurrence after liver transplantation. Surg Oncol, 25(4):419-428.

[13]Gugenheim J, Bredt LC, Iannelli A, et al., 2013. Recurrence after liver transplantation for hepatocellular carcinoma according to up-to-seven criteria. Hepatogastroenterology, 60(124):799-806.

[14]Guo R, Feng X, Xiao S, et al., 2015. Short- and long-term outcomes of hepatectomy with or without radiofrequency-assist for the treatment of hepatocellular carcinomas: a retrospective comparative cohort study. Biosci Trends, 9(1):65-72.

[15]Hameed B, Mehta N, Sapisochin G, et al., 2014. Alpha-fetoprotein >1000 ng/ml as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting Milan criteria. Liver Transpl, 20(8):945-951.

[16]Hirokawa F, Hayashi M, Miyamoto Y, et al., 2015. Predictors of poor prognosis by recurrence patterns after curative hepatectomy for hepatocellular carcinoma in Child-Pugh classification A. Hepatogastroenterology, 62(137):164-168.

[17]Ioannou GN, Perkins JD, Carithers RL, 2008. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival. Gastroenterology, 134(5):1342-1351.

[18]Kanai T, Hirohashi S, Upton MP, et al., 1987. Pathology of small hepatocellular carcinoma. A proposal for a new gross classification. Cancer, 60(4):810-819.

[19]Kashkoush S, El Moghazy W, Kawahara T, et al., 2014. Three-dimensional tumor volume and serum alpha-fetoprotein are predictors of hepatocellular carcinoma recurrence after liver transplantation: refined selection criteria. Clin Transplant, 28(6):728-736.

[20]Kim H, Park MS, Park YN, et al., 2009. Preoperative radiologic and postoperative pathologic risk factors for early intra-hepatic recurrence in hepatocellular carcinoma patients who underwent curative resection. Yonsei Med J, 50(6):789-795.

[21]Kim JH, Sinn DH, Gwak GY, et al., 2016. Factors determining long-term outcomes of hepatocellular carcinoma within the Milan criteria: liver transplantation versus locoregional therapy: a retrospective cohort study. Medicine (Baltimore), 95(35):e4735.

[22]Kumaran V, 2014. Role of liver transplantation for hepatocellular carcinoma. J Clin Exp Hepatol, 4(Suppl 3):S97-S103.

[23]Kwon CH, Kim DJ, Han YS, et al., 2007. HCC in living donor liver transplantation: can we expand the Milan criteria? Dig Dis, 25(4):313-319.

[24]Lai Q, Avolio AW, Manzia TM, et al., 2011. Role of alpha-fetoprotein in selection of recipients with hepatocellular carcinoma waiting for liver transplantation: must we reconsider it? Int J Biol Markers, 26(3):153-159.

[25]Lai Q, Avolio AW, Manzia TM, et al., 2012. Combination of biological and morphological parameters for the selection of recipients with hepatocellular carcinoma waiting for liver transplantation. Clin Transplant, 26(2):E125-E131.

[26]Lee KW, Yi NJ, Suh KS, 2014. Section 5. Further expanding the criteria for HCC in living donor liver transplantation: when not to transplant: SNUH experience. Transplantation, 97(Suppl 8):S20-S23.

[27]Lei JY, Wang WT, Yan LN, 2013. Up-to-seven criteria for hepatocellular carcinoma liver transplantation: a single center analysis. World J Gastroenterol, 19(36):6077-6083.

[28]Li Z, Zhao X, Jiang P, et al., 2016. HBV is a risk factor for poor patient prognosis after curative resection of hepatocellular carcinoma: a retrospective case-control study. Medicine (Baltimore), 95(31):e4224.

[29]Mazzaferro V, Regalia E, Doci R, et al., 1996. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med, 334(11):693-699.

[30]Mazzaferro V, Llovet JM, Miceli R, et al., 2009. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol, 10(1):35-43.

[31]McHugh PP, Gilbert J, Vera S, et al., 2010. Alpha-fetoprotein and tumor size are associated with microvascular invasion in explanted livers of patients undergoing transplantation with hepatocellular carcinoma. HPB (Oxford), 12(1):56-61.

[32]Merli M, Nicolini G, Gentili F, et al., 2005. Predictive factors of outcome after liver transplantation in patients with cirrhosis and hepatocellular carcinoma. Transpl Proc, 37(6):2535-2540.

[33]Molmenti PE, Marsh WJ, Dvorchik I, et al., 1999. Hepatobiliary malignancies: primary hepatic malignant neoplasms. Surg Clin North Am, 79(1):43-57.

[34]Müller V, Fortsch T, Gündelm M, et al., 2013. Long-term outcome of liver transplantation as treatment modality in patients with hepatocellular carcinoma in cirrhosis: a single-center experience. Transplant Proc, 45(5):1957-1960.

[35]Patel MS, Kohn R, Kratz JR, et al., 2015. The race to liver transplantation: a comparison of patients with and without hepatocellular carcinoma from listing to post transplantation. J Am Coll Surg, 220(6):1001-1007.

[36]Pawlik TM, Delman KA, Vauthey JN, et al., 2005. Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl, 11(9):1086-1092.

[37]Reddy SS, Civan JM, 2016. From Child-Pugh to model for end-stage liver disease: deciding who needs a liver transplant. Med Clin North Am, 100(3):449-464.

[38]Silva MF, Sapisochin G, Strasser SI, et al., 2013. Liver resection and transplantation offer similar 5-year survival for Child-Pugh-Turcotte A HCC-patients with a single nodule up to 5 cm: a multicenter, exploratory analysis. Eur J Surg Oncol, 39(4):386-395.

[39]Sohn W, Paik YH, Kim JM, et al., 2014. HBV DNA and HBsAg levels as risk predictors of early and late recurrence after curative resection of HBV-related hepatocellular carcinoma. Ann Surg Oncol, 21(7):2429-2435.

[40]Toso C, Asthana S, Bigam DL, et al., 2009. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the scientific registry of transplant recipients database. Hepatology, 49(3):832-838.

[41]Varona MA, Soriano A, Aguirre-Jaime A, et al., 2015. Risk factors of hepatocellular carcinoma recurrence after liver transplantation: accuracy of the alpha-fetoprotein model in a single-center experience. Transplant Proc, 47(1):84-89.

[42]WHO (World Health Organization), 2016. Hepatitis B. http://www.who.int/mediacentre/factsheets/fs204/en [Accessed on Jan. 28, 2017].

[43]Wong LL, Naugler WE, Schwartz J, et al., 2013. Impact of locoregional therapy and alpha-fetoprotein on outcomes in transplantation for liver cancer: a UNOS Region 6 pooled analysis. Clin Transplant, 27(1):E72-E79.

[44]Xu X, Ke QH, Shao ZX, et al., 2009. The value of serum α-fetoprotein in predicting tumor recurrence after liver transplantation for hepatocellular carcinoma. Dig Dis Sci, 54(2):385-388.

[45]Xu X, Lu D, Ling Q, et al., 2016. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria. Gut, 65(6):1035-1041.

[46]Yang SH, Suh KS, Lee HW, et al., 2007. A revised scoring system utilizing serum alphafetoprotein levels to expand candidates for living donor transplantation in hepatocellular carcinoma. Surgery, 141(5):598-609.

[47]Yao FY, Ferrell L, Bass NM, et al., 2001. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology, 33(6):1394-1403.

[48]Yao FY, Xiao L, Bass NM, et al., 2007. Liver transplantation for hepatocellular carcinoma: validation of the UCSF expanded criteria based on preoperative imaging. Am J Transplant, 7(11):2587-2596.

[49]Yao FY, Mehtam N, Flemming J, et al., 2015. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology, 61(6):1968-1977.

[50]Zavaglia C, de Carlis L, Alberti AB, et al., 2005. Predictor of longterm survival after liver transplant at ion for hepatocellular carcinoma. Am J Gastroenterol, 100(12):2708-2716.

[51]Zhang Q, Shang L, Zang Y, et al., 2014. α-Fetoprotein is a potential survival predictor in hepatocellular carcinoma patients with hepatitis B selected for liver transplantation. Eur J Gastroenterol Hepatol, 26(5):544-552.

[52]Zheng SS, Xu X, Wu J, et al., 2008. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation, 85(12):1726-1732.